Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

No Patent Board Sanctions For Bass; Celgene Denied

This article was originally published in Scrip

Executive Summary

Celgene failed to convince the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) to impose sanctions against Kyle Bass, chief investment officer at Hayman Capital Management, and his self-created Coalition for Affordable Drugs, and dismiss his inter partes review (IPR) petitions on the grounds of abuse of process and improper use of the proceedings.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register